01/11/2021 — NEVE ILAN, Israel — (BUSINESS WIRE)

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX) will report its results for the third quarter ended September 30, 2021 before market on Wednesday, November 17, 2021. Ran Poliakine, Chairman and Chief Executive Officer, and Erez Meltzer, Director (appointed CEO effective January 1, 2022), will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Interested parties may access the conference call by dialing (877) 550-3765 (Domestic) or (409) 937-8962 (International) and reference Access Code 7872065. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Nanox website at Investors | Nano-X Imaging LTD. (nanox.vision)

About Nanox

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging services for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to Nanox’s ability to complete development of the Nanox.ARC; Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; Nanox’s ability to conduct business globally; and risks and business interruptions related to the COVID-19 pandemic, among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2020 and subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox’s expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005551/en/

CONTACT:

Mike Cavanaugh
Westwicke ICR
Mike.Cavanaugh@westwicke.com

Tamar Aharon Cohen
Nanox Imaging
IR@nanox.vision